Lanean...
Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review
Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety....
Gorde:
| Egile Nagusiak: | , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Taylor & Francis Group
2021-01-01
|
| Saila: | Pulmonology |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.tandfonline.com/doi/10.1016/j.pulmoe.2020.07.003 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|